- Home
- UNCY vs PEPG Comparison
UNCY vs PEPG Comparison
Compare UNCY & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- PEPG
- Stock Information
- Founded
- UNCY 2016
- PEPG 2018
- Country
- UNCY United States
- PEPG United States
- Employees
- UNCY N/A
- PEPG N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- PEPG Health Care
- Exchange
- UNCY Nasdaq
- PEPG Nasdaq
- Market Cap
- UNCY 58.7M
- PEPG 64.2M
- IPO Year
- UNCY 2021
- PEPG 2022
- Fundamental
- Price
- UNCY $0.62
- PEPG $1.37
- Analyst Decision
- UNCY Strong Buy
- PEPG Buy
- Analyst Count
- UNCY 4
- PEPG 3
- Target Price
- UNCY $5.50
- PEPG $14.67
- AVG Volume (30 Days)
- UNCY 1.0M
- PEPG 486.5K
- Earning Date
- UNCY 03-27-2025
- PEPG 03-05-2025
- Dividend Yield
- UNCY N/A
- PEPG N/A
- EPS Growth
- UNCY N/A
- PEPG N/A
- EPS
- UNCY N/A
- PEPG N/A
- Revenue
- UNCY N/A
- PEPG N/A
- Revenue This Year
- UNCY N/A
- PEPG N/A
- Revenue Next Year
- UNCY N/A
- PEPG N/A
- P/E Ratio
- UNCY N/A
- PEPG N/A
- Revenue Growth
- UNCY N/A
- PEPG N/A
- 52 Week Low
- UNCY $0.20
- PEPG $1.16
- 52 Week High
- UNCY $1.80
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- UNCY 51.79
- PEPG 31.82
- Support Level
- UNCY $0.57
- PEPG $1.16
- Resistance Level
- UNCY $0.65
- PEPG $1.60
- Average True Range (ATR)
- UNCY 0.05
- PEPG 0.14
- MACD
- UNCY 0.01
- PEPG 0.11
- Stochastic Oscillator
- UNCY 76.36
- PEPG 48.28
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.